person · Reporting owner

Ellis Ronald J. Jr.

Disclosed activity across 2 companies

Tapewire entity: 112609
SEC CIK: 0001790670

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Pacira BioSciences, Inc.PCRX · Entity 4928	Chief Strategy Officer	June 06, 2023	June 08, 2023
TELA Bio, Inc.TELA · Entity 7381	Director · 10% owner	November 13, 2019	November 14, 2019

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Pacira BioSciences, Inc.

Report date June 06, 2023 · Filed June 08, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	30,909	Ending reported balance After 2023-06-07 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-06-06 · Sale · Disposed 1,114 · Balance 32,071 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Row 2 · 2023-06-07 · Sale · Disposed 1,162 · Balance 30,909 F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.

TELA Bio, Inc.

Report date November 13, 2019 · Filed November 14, 2019

Jointly reported with Pacira BioSciences, Inc.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectBy Pacira BioSciences, Inc.	774,056	Reported balance After 2019-11-13 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-11-13 · Conversion · Acquired 580,357 · Balance 774,056 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2: Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectBy Pacira BioSciences, Inc.	0	Reported balance After 2019-11-13 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-11-13 · Conversion · Disposed 14,329,052 · Balance 0 F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date.

F2: Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a).

F3: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 07, 2023 Filed Jun 8, 2023 01:20 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	1,162	$37.87	$43,999.13	Disclosure SEC source: 0001209191-23-035255 · doc4.xml · nonDerivative · entry 2 Ellis Ronald J. Jr. · CIK 0001790670 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,909 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document
June 06, 2023 Filed Jun 8, 2023 01:20 UTC	Pacira BioSciences, Inc. PCRX · Entity 4928	SaleCommon Stock	1,114	$38.99	$43,435.97	Disclosure SEC source: 0001209191-23-035255 · doc4.xml · nonDerivative · entry 1 Ellis Ronald J. Jr. · CIK 0001790670 · Chief Strategy Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,071 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document
November 13, 2019 Filed Nov 14, 2019 02:06 UTC	TELA Bio, Inc. TELA · Entity 7381	ConversionSeries B Preferred Stock · Derivative	14,329,052	$0.00	$0.00	Disclosure SEC source: 0001192482-19-000432 · edgar.xml · derivative · entry 2 Ellis Ronald J. Jr. · CIK 0001790670 · Director · 10% owner Pacira BioSciences, Inc. · CIK 0001396814 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pacira BioSciences, Inc. Disclosed balance after: 0 Underlying: Common Stock · 580,357 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F3 · derivative.underlying_shares: Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019. Read SEC document
November 13, 2019 Filed Nov 14, 2019 02:06 UTC	TELA Bio, Inc. TELA · Entity 7381	ConversionCommon Stock	580,357	Not disclosed	Not disclosed	Disclosure SEC source: 0001192482-19-000432 · edgar.xml · nonDerivative · entry 1 Ellis Ronald J. Jr. · CIK 0001790670 · Director · 10% owner Pacira BioSciences, Inc. · CIK 0001396814 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Pacira BioSciences, Inc. Disclosed balance after: 774,056 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date. F2 · balance_after: Reflects 193,699 shares of common stock received as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a). Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.